Diabetic individuals with COVID-19 exhibit reduced efficacy of gliptins in inhibiting dipeptidyl peptidase 4 (DPP4). A suggested explanation for increased COVID-19 susceptibility in patients with type 2 diabetes mellitus (T2DM)

• Published in: Life sciences (1973) Vol. 336; p. 122292
• Main Authors: Mora-Rodríguez, José María, Sánchez, Belén G, Bort, Alicia, Díaz-Yuste, Alba, Ballester-González, Rubén, Arrieta, Francisco, Sebastián-Martín, Alba, Díaz-Laviada, Inés
• Format: Journal Article
• Language: English
• Published: Netherlands 01.01.2024
• Subjects: COVID-19; DPP4; Type 2 diabetes; Enzymatic activity; Gliptins

Dipeptidyl peptidase 4 (DPP4) has been proposed as a coreceptor for SARS-CoV-2 cellular entry. Considering that type 2 diabetes mellitus (T2DM) has been identified as the most important risk factor for SARS-CoV-2, and that gliptins (DPP4 inhibitors) are a prescribed diabetic treatment, this study ai...